Fig. 5: Soquelitinib enhances CD19 CAR-T cell efficacy in ALL mouse models.
From: ITK-targeted immune remodeling enhanced the efficacy of anti-CD19 CAR-T cell therapy
A NCG mice received intravenous injection of luciferase-expressing NALM6 cells (5 × 10⁶ cells/mouse) on Day (−7) to establish ALL mouse models. Anti-CD19 CAR-T cells (2 × 10⁶ cells/mouse) were infused ± soquelitinib (30 mg/kg, oral gavage daily) on Day 0. B Tumor burden quantification: Bioluminescent flux (scale: 10⁸ photons/sec/cm²/sr) measured in regions of interest (ROI) following IVIS imaging at indicated timepoints; n = 6. C Representative in vivo bioluminescence: Images visualize the marked attenuation of tumor signal in the combination group on Day 10 (scale: photons/sec/cm²/sr) and Day 14 (scale: photons/sec/cm²/sr). D Survival analysis: Kaplan-Meier curves demonstrate prolonged survival in the combination group; n = 6. E NCG mice received intravenous injection of luciferase-expressing NALM6 cells (5 × 10⁶ cells/mouse) on Day (−7) to establish ALL mouse models. These mice were treated with either soquelitinib (30 mg/kg, oral gavage daily) or vehicle control, starting on Day 0, without any CAR-T cell infusion. Kaplan-Meier analysis revealed no significant survival benefit with soquelitinib treatment compared to the control group; n = 6–7.
